COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Protocol No
HJKC3-0002
Principal Investigator
Ehab Atallah
Phase
II
Summary
Recently, clinical trials have looked at patients who are attempting to stop TKI medications for a second time after relapsing during their first stopping attempt. These studies have shown that it is possible to stop a second time and be monitored for recurrence. The purpose of this study is to determine if adding ruxolitinib to a TKI prior to a second attempt at stopping a TKI will lead to prolonged treatment free remission.
Description
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
Participating Institutions
Memorial Sloan Kettering Cancer Center - Bergen
Moorland Reserve Health Center
Moffitt Cancer Center University of South Florida
OHSU - Oregon Health & Science University Knight Cancer Institute
Fred Hutchinson Cancer Research Center
Froedtert Hospital
Roswell Park Cancer Institute
Memorial Sloan Kettering Cancer Center
Status
OPEN TO ACCRUAL